TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Prevalence of cardiovascular morbidities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: bone thickness at T0
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: bone thickness at T1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: bone thickness at T2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: severity of dysphonia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: severity of dysphagia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Negative Symptom Assessment Scale (NSA-16) total score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of participants showing adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in salivary pH
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reproducibility of head movement amplitude measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reproducibility of mechanical resistance strength intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Reproducibility of time until appearance of mechanical resistance strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Linear bone growth
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Mortality in 7 days for any cause
Endpoint domain: Mortality/survival
Primary endpoint: Changes in leg press muscle power
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in end systolic volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in the Scale for the assessment and rating of ataxia (SARA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Multiple pregnancy rates
Endpoint domain: Mortality/survival
Primary endpoint: Change in Visual Analogue Scale for Major Nasal Symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: children's compliance with growth hormone treatment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Proportion of patients with a high quality after visit summary
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Proportion of patients with discharge summary timeliness
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Proportion of patients Complete Medication Reconciliation by Discharge
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Proportion of patients achieving a high quality 'perfect' discharge
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Amount of keratinised tissues
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in pre-dialysis systolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Duration of Viral Shedding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Reduction in Respiratory Failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Reduction in Cardiac/Circulatory Failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Critical threshold of SpHb drop during cesarean delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Time of SpHb drop correlation with hemorrhagic intervention decision
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence, severity, and duration of adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Determination of a maximum tolerated dose
Endpoint domain: Adverse events/effects
Primary endpoint: Surgical site pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Active and passive range of motion (ROM) of interphalangeal joint (IPJ) and metacarpal-phalangeal joint (MPJ)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Satisfaction level after surgery
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mucositis Evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Best Corrected Visual Acuity (BCVA) ≥15 Letters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gamma H2AX levels in peripheral blood lymphocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Symptom Checklist Short Form (SCL-K11)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Rate of Radiation-Induced Lung Injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Rates of Grade >3 Radiation Pneumonitis
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Dermatology Life Quality Index (DLQI) at Week 8 From Baseline
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Resolution of Nonalcoholic Steatohepatitis Without Worsening of Fibrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver-related outcomes
Primary endpoint: Time to Long-term Outcome Composed of All-cause Mortality, Cirrhosis, and Liver-related Clinical Outcomes
Endpoint domain: Mortality/survival
Primary endpoint: The Persian Functional Rating Index (FRI)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Distribution volume (VT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Estimation of the plasma concentration resulting in 50% receptor occupancy (Ki, pl)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Opportunistic infection
Endpoint domain: Adverse events/effects
Primary endpoint: Cocaine withdrawal
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Patients Who Maintained Vision
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Change From Baseline in Wong Baker Faces Pain Rating Scale of Pain Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Change From Baseline in Visual Rating Scale of Swelling Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Reduction in Bacterial Count by quantitative Polymerase Chain Reaction (q-PCR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: AUCtau of ENTO
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of ENTO
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Development of cirrhosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Postoperative functional outcome
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Relapse of depression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Rates of Grade 2 and Higher Alanine Aminotransferase (ALT) Elevations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Number of unprotected sex acts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number of unclean drug injections
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number of sexually transmitted infections
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Serious adverse cardio-respiratory events
Endpoint domain: Adverse events/effects
Primary endpoint: Total cost of patient care
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Decrease in Left Ventricle Ejection Fraction (LVEF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: respiratory impact
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Thoracic ROM
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: TEG (clotting) parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in frequency of observed head nodding and other seizure activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Event-related brain potentials
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Task Performance
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Health related quality of life, physical component summary score (HRQOL-PCS)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Rate of germline BAP1 mutations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lumbar Bone Mineral Density
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Symptom distress
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Elasticity levels of the internal os
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Change in stuttered syllables
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: changes in total motor scores (TMSC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of bacteraemia and fungemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Percentage of Participants Who Experienced Cataplexy Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants Who Experienced Sleep Paralysis AEs
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants Who Experienced Complex Sleep-related Behaviors AEs
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants Who Experienced Falls AEs
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants Who Experienced Suicidal Ideation and/or Behavior AEs
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants Who Experienced Hypnagogic/Hypnopompic Hallucinations AEs
Endpoint domain: Adverse events/effects
Primary endpoint: Total body water (TBW) in kg
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Body weight (BW) in kg
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: acute cellular rejection rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mean total body weight loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Proportion of participants who lose 5% total body weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: GI Bleeding characteristics
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Patient Reported Symptom Severity
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Patient Reported Symptom Interference
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Completion Rate of 8-cycle Adjuvant Chemotherapy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: percent of eligible patients who refuse randomization
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: percent of patients who complete 9 sessions of BA treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: percent of BA homework assignments that are completed
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: percent of monthly assessments obtained
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Social Functioning Score
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Number of patients with significant changes from baseline in vital signs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients with abnormal changes from baseline in electrocardiogram (ECG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of patients with abnormal changes from baseline in laboratory tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: daptomycin dosage after intravenous route
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: daptomycin dosage after subcutaneous route
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Rate of Complete Cytogenetic Response (CCyR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Rate of Major Molecular Response (MMR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Overall maternal and fetal health
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of DTG-based maintenance therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline in Female Sexual Function Index questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Vaginal Cytology Improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in vaginal acidity measure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NHF Use for 30 Days Following Discharge
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Cmax of Aclidinium Bromide, Its Metabolites and Formoterol Fumarate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC(Last) of Aclidinium Bromide, Its Metabolites and Formoterol Fumarate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Css,Max of Aclidinium Bromide, Its Metabolites and Formoterol Fumarate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post-operative inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum plasma concentration (Cmax) of Lacosamide (LCM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 1-year Progression Free Survival (PFS) Rate
Endpoint domain: Mortality/survival
Primary endpoint: Neuropathic Pain Monthly Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Death or survival
Endpoint domain: Mortality/survival
Primary endpoint: Buprenorphine concentration in blood serum (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate reduction in Depressive symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Rate reduction in Anxiety symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Rate reduction in Post traumatic Stress symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Rate reduction in Perceived stress level
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of Adverse Events at Six Months Post-Implantation
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Severe Adverse Events at Six Months Post-Implantation
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Ocular Adverse Events at Six Months Post-Implantation
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Non-Ocular Adverse Events at Six Months Post-Implantation
Endpoint domain: Adverse events/effects
Primary endpoint: Experience of lenalidomide use
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Proportion of women completing follow-ups
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Intracranial Disease Control Rate (DCR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Perinatal survival rate
Endpoint domain: Mortality/survival
Primary endpoint: Neonatal renal function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Percentage of Participants in Complete Renal Response (CR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Reduction of circulating inflammatory markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Reduction of acute phase reaction proteins
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in depression from baseline to 12 weeks
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in pain from baseline to 12 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in fatigue from baseline to 12 weeks
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Time to death, high-urgent heart transplantation or ventricular assist device (VAD)
Endpoint domain: Mortality/survival
Primary endpoint: Time to non-fatal HF event
Endpoint domain: Mortality/survival
Primary endpoint: Response rate duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of SpHb
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gene expression levels of mitofusin 2 and uncoupling protein 2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical and microbiological cure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bacterial abundances
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in baseline frequency of maximum of cross-spectrum
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Treatment emergent adverse events (TEAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Postpartum Clinic Attendance
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Time to red blood cell (RBC) improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Mean Nausea Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference in Peak plasma concentration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference in systemic exposure: Area under the plasma concentration versus time curve (AUC-0last)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference in dose adjusted systemic exposure: Area under the plasma concentration versus time curve (AUC-0inf)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference in time at which the Cmax is observed (Tmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anterior hippocampal volume (change)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Incidence of Events
Endpoint domain: Adverse events/effects
Primary endpoint: Change From Baseline in Visual Analogue Scale (VAS) Ocular Tolerability Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Person-centered Family Planning Scale Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Experience of providing FP counseling
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Acute toxicity rates
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Bcl-2 m-RNA levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ability to challenge wrong decisions
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Number of Drinks Consumed at Lab Session (Day 7)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Monocytes phagocytic capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Days presenting upper respiratory tract symptoms
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: CSF leak
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Volume of myocardic cavity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Thickness of the myocard
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Serum Prostate Specific Antigen (PSA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Serum Vascular Endothelial Growth Factor (VEGF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Serum Hepatocyte Growth Factor (HGF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Negative Verbalizations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Positive Peer Behavior
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Ultrasound evaluation of needle placement accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline in 24-Hour Urine Calcium
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change from Baseline in Serum Calcium
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes